From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
M0 events/ total | M1 events/ total | p-value | T0 events/ total | T1/2 events/ total | p-value | C0 events/ total | C1/2 events/ total | p-value | |
---|---|---|---|---|---|---|---|---|---|
Full clinical remissiona | 8/48 (17%) | 0/17 (0%) | 0.099 | 6/39 (15%) | 2/26 (8%) | 0.460 | 4/45 (9%) | 4/20 (20%) | 0.238 |
GFR-loss ≥15 ml/min | 14/51 (27%) | 9/18 (50%) | 0.092 | 11/40 (28%) | 12/29 (41%) | 0.302 | 16/47 (34%) | 7/22 (32%) | 1.000 |
ESRDb | 7/51 (14%) | 1/18 (6%) | 0.671 | 1/40 (3%) | 7/29 (24%) | 0.008 | 4/47 (9%) | 4/22 (18%) | 0.255 |
Disappearance of microhematuria | 11/34 (32%) | 3/15 (20%) | n.d. c | 10/29 (35%) | 4/20 (20%) | n.d. c | 10/34 (29%) | 4/15 (27%) | 1.000 |
Absolute annual GFR change (ml/min/1.73m2) | −0.79 ± 4.50 | −5.06 ± 5.17 | 0.002 | −2.05 ± 5.40 | −2.01 ± 4.54 | 0.362 | − 2.66 ± 5.02 | −0.82 ± 5.02 | 0.131 |